Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Rhea-AI Summary

Vaccitech plc (NASDAQ: VACC) announced a presentation regarding its Phase 1b/2a study of VTP-300, an immunotherapy for chronic hepatitis B, at the AASLD - The Liver Meeting^® from November 4-8, 2022. The poster details the therapeutic vaccination's safety, tolerability, and ability to stimulate immune responses, as well as durable reductions in hepatitis B surface antigen. The study combines an adenoviral vector with a pox virus and is presented by Dr. Young-Suk Lim. Key executives will also attend the meeting for potential partnerships.

Positive

• Presentation of Phase 1b/2a study results for VTP-300 at AASLD.
• Demonstrated safety and tolerability of VTP-300.
• Meaningful reductions in hepatitis B surface antigen observed.

Negative

• None.

OXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company will be presenting an update on its Phase 1b/2a study of VTP-300, Vaccitech’s novel immunotherapy for chronic hepatitis B, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting^®, in Washington, D.C., November 4 – 8, 2022.

Poster Presentation Details:

Title:	Phase 1b/2a Study of Heterologous ChAdOx1-HBV/MVA-HBV Therapeutic Vaccination (VTP-300) Combined with Low-Dose Nivolumab (LDN) in Virally-Suppressed Patients with CHB on Nucleos(t)ide Analogues
Abstract Number:	38918
Final Poster Number:	5026
Presenter:	Dr. Young-Suk Lim, Professor of Gastroenterology in the Liver Center at University of Ulsan College of Medicine and clinical trial investigator for Vaccitech
Time/Date:	1:00 p.m. – 2:00 p.m. EST on Monday, November 7, 2022

In addition, Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp and Director, Programme Management, Dr. Henrik Sorensen will also be attending AASLD – The Liver Meeting^®.

Event:	Study of Liver Disease (AASLD) - The Liver Meeting®, Washington, D.C.
Date:	Friday, November 4 – Tuesday, November 8
Attending:	Dr. Thomas G. Evans, Nick Fullenkamp, Dr. Henrik Sorensen
	Available to participate in 1x1 partnering meetings

About VTP-300
VTP-300 is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx) and boosted with a pox virus (MVA). Both vectors have been modified to improve safety, enhance the immune response they induce and include HBV specific antigens including core, polymerase and surface antigen. Clinical data generated to date has demonstrated this regimen to be generally safe and well-tolerated, that antigen specific T cell responses are stimulated to each antigen and there were meaningful and durable reductions in hepatitis B surface antigen when this regimen is given alone or when given in combination with a low dose of nivolumab at the boost.

About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

IR contacts: Christopher M. Calabrese  Managing Director  LifeSci Advisors 917-680-5608 ccalabrese@lifesciadvisors.com	Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 kgardner@lifesciadvisors.com
Media contact: Mike Beyer SAM BROWN, INC 312-961-2502 mikebeyer@sambrown.com
Company contact: Jonothan Blackbourn IR & PR Manager Vaccitech IR@vaccitech.co.uk

FAQ

What results are expected from Vaccitech's VTP-300 study?

Vaccitech aims to showcase the safety, tolerability, and immune response generated by VTP-300 during the AASLD presentation.

When and where is the AASLD presentation for VTP-300?

The presentation will take place on November 7, 2022, during the AASLD meeting in Washington, D.C.

Who is presenting the VTP-300 study results?

Dr. Young-Suk Lim from the University of Ulsan College of Medicine will present the results.

What is VTP-300 developed for?

VTP-300 is developed as an immunotherapy for chronic hepatitis B.

What are the implications of the VTP-300 study for the market?

Positive results could enhance Vaccitech's market position in immunotherapies for chronic viral infections.